NIFTY 50 23351 ▲ (0.03%)
NIFTY NEXT 50 64794.05 ▼ (0.48%)
NIFTY 100 24032.95 ▼ (0.07%)
NIFTY MIDCAP 100 54944.75 ▼ (0.29%)
NIFTY SMALLCAP 100 17871.85 ▲ (0.04%)
NIFTY SMALLCAP 250 16857.3 ▲ (0.09%)
NIFTY MIDCAP SELECT 12279.4 ▼ (0.62%)
NIFTY TOTAL MARKET 12298.95 ▼ (0.05%)
NIFTY BANK 49217.45 ▼ (0.27%)
SENSEX 76882.63 ▼ (0.25%)
BSE BANKEX 55818.16 ▼ (0.39%)

Samrat Pharmachem : Q4 2024 Financial Quarterly Report : YoY Sales Up 19.52 %, QoQ Up 34.06 %

Image is loading

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 19.52 % in the past year, substantial increase in net sales/revenue by 34.06 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 1450 %. Marginal decrease of -26.19% in other income during this quarter.
  • Profit over the Year and quarter: Challenges in sustaining profitability for Samrat Pharmachem Ltd.. Profit dropped by -287.25 % Year to Year, Samrat Pharmachem Ltd.’s profitability increased by 305.52 % in this quarter.
  • EPS over the Year and quarter: EPS declined by -287.55 % Year to Year. EPS increased by 307.21 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Samrat Pharmachem Ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 69.181 Cr Rs. 61.674 Cr Rs. 82.683 Cr + 34.06 % + 19.52 %
Expenses Rs. 69.67 Cr Rs. 61.56 Cr Rs. 81.32 Cr + 32.1 % + 16.72 %
Operating Profit Rs. -0.49 Cr Rs. 0.11 Cr Rs. 1.36 Cr + 1136.36 % + 377.55 %
OPM % -0.71 % 0.18 % 1.64 % + 1.46 % + 2.35 %
Other Income Rs. 0.02 Cr Rs. 0.42 Cr Rs. 0.31 Cr -26.19 % + 1450 %
Interest Rs. 0.17 Cr Rs. 0.23 Cr Rs. 0.11 Cr -52.17 % -35.29 %
Depreciation Rs. 0.16 Cr Rs. 0.16 Cr Rs. 0.16 Cr + 0 % + 0 %
Profit before tax Rs. -0.8 Cr Rs. 0.14 Cr Rs. 1.4 Cr + 900 % + 275 %
Tax % -5.82 % 143.97 % 0.43 % -143.54 % + 6.25 %
Net Profit Rs. -0.75 Cr Rs. 0.34 Cr Rs. 1.4 Cr + 311.76 % + 286.67 %
EPS in Rs Rs. -2.41 Rs. 1.11 Rs. 4.52 + 307.21 % + 287.55 %


Today, we’re looking at Samrat Pharmachem Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 19.52 %. However, it did see a marginal increase of 34.06 % from the previous quarter. Expenses ticked up slightly by 32.1 % quarter-on-quarter, aligning with the annual rise of 16.72 %. Operating profit, while up 377.55 % compared to last year, faced a quarter-on-quarter increase of 1136.36 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.35 %, but an expansion of 1.46 % sequentially. Other income fell by -26.19 % compared to the last quarter, despite an annual growth of 1450 %. Interest expenses dropped significantly by -52.17 % from the previous quarter, yet the year-over-year decrease remains at a moderate -35.29 %. Depreciation costs climbed by 0 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 0 %. Profit before tax grew annually by 275 % but saw an increase from the preceding quarter by 900 %.
Tax expenses as a percentage of profits increased slightly by 6.25 % compared to last year, with a more notable quarter-on-quarter decrease of -143.54 %. Net profit rose by 286.67 % year-on-year but experienced a 311.76 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 287.55 % but a quarterly rise of 307.21 %. In summary, Samrat Pharmachem Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 69.181 Cr Rs. 61.674 Cr Rs. 82.683 Cr + 34.06 % + 19.52 %
Expenses Rs. 69.67 Cr Rs. 61.56 Cr Rs. 81.32 Cr + 32.1 % + 16.72 %
Operating Profit Rs. -0.49 Cr Rs. 0.11 Cr Rs. 1.36 Cr + 1136.36 % + 377.55 %
Net Profit Rs. -0.75 Cr Rs. 0.34 Cr Rs. 1.4 Cr + 311.76 % + 286.67 %
EPS in Rs Rs. -2.41 Rs. 1.11 Rs. 4.52 + 307.21 % + 287.55 %


In reviewing Samrat Pharmachem Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 19.52 % year-on-year growth, however, there was a minor increase of 34.06 % from the previous quarter. Expenses rose by 16.72 % compared to the previous year, with a 32.1 % increase quarter-on-quarter. Operating Profit surged by 377.55 % annually, and saw a 1136.36 % increase from the last quarter.
Net Profit showed yearly increase of 286.67 %, and experienced a 311.76 % increase from the previous quarter. Earnings Per Share (EPS) rose by 287.55 % annually, however rose by 307.21 % compared to the last quarter. In essence, while Samrat Pharmachem Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Samrat Pharmachem “]

Related Post